MIPL-Logo

3decades

 

MIRA INFORM REPORT

 

 

Report No. :

497064

Report Date :

09.03.2018

 

 

 

IDENTIFICATION DETAILS

 

Name :

CARL ZEISS MEDITEC CO LTD

 

 

Registered Office :

13-11 Yotsuya Honshiocho Shinjukuku Tokyo 160-0003

 

 

Country :

Japan

 

 

Financials (as on) :

30.09.2017

 

 

Date of Incorporation :

December 1991

 

 

Com. Reg. No.:

0111-01-017533

 

 

Legal Form :

Limited Company

 

 

Line of Business :

A trading firm for import, export & wholesale of medical equipment, ophthalmic systems, other

 

 

No. of Employees :

131

 

 

RATING & COMMENTS

(Mira Inform has adopted New Rating mechanism w.e.f. 23rd January 2017)

 

MIRA’s Rating :

A

 

Credit Rating

Explanation

Rating Comments

A

Acceptable Risk

Business dealings permissible with moderate risk of default

 

Maximum Credit Limit :

Yen 233.7 million

 

 

Status :

Good

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List

 

Country Name

Previous Rating

(30.09.2017)

Current Rating

(31.12.2017)

Japan

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low Risk

 

A2

Moderately Low Risk

 

B1

Moderate Risk

 

B2

Moderately High Risk

 

C1

High Risk

 

C2

Very High Risk

 

D

 


 

JAPAN - ECONOMIC OVERVIEW

 

Over the past 70 years, government-industry cooperation, a strong work ethic, mastery of high technology, and a comparatively small defense allocation (slightly less than 1% of GDP) have helped Japan develop an advanced economy. Two notable characteristics of the post-World War II economy were the close interlocking structures of manufacturers, suppliers, and distributors, known as keiretsu, and the guarantee of lifetime employment for a substantial portion of the urban labor force. Both features have significantly eroded under the dual pressures of global competition and domestic demographic change.

Measured on a purchasing power parity basis that adjusts for price differences, Japan in 2017 stood as the fourth-largest economy in the world after first-place China, which surpassed Japan in 2001, and third-place India, which edged out Japan in 2012. For three postwar decades, overall real economic growth was impressive - a 10% average in the 1960s, 5% in the 1970s, and 4% in the 1980s. Growth slowed markedly in the 1990s, averaging just 1.7%, largely because of the aftereffects of inefficient investment and the collapse of an asset price bubble in the late 1980s, which entailed considerable time for firms to reduce excess debt, capital, and labor. Modest economic growth continued after 2000, but the economy has fallen into recession four times since 2008.

Japan enjoyed an uptick in growth in 2013 on the basis of Prime Minister Shinzo ABE’s “Three Arrows” economic revitalization agenda - dubbed “Abenomics” - of monetary easing, “flexible” fiscal policy, and structural reform. Led by the Bank of Japan’s aggressive monetary easing, Japan is making modest progress in ending deflation, but demographic decline – a low birthrate and an aging, shrinking population – poses a major long-term challenge for the economy. The government currently faces the quandary of balancing its efforts to stimulate growth and institute economic reforms with the necessity of addressing its sizable public debt, which stands at 235% of GDP. To help raise government revenue, Japan adopted legislation in 2012 to gradually raise the consumption tax rate. However, the first such increase, in April 2014, led to another recession, so Prime Minister ABE has twice postponed the next increase, now scheduled for October 2019. Structural reforms to unlock productivity are seen as central to strengthening the economy in the long-run.

Scarce in critical natural resources, Japan has long been dependent on imported energy and raw materials. After the complete shutdown of Japan’s nuclear reactors following the earthquake and tsunami disaster in 2011, Japan's industrial sector has become even more dependent than before on imported fossil fuels. However, ABE’s government is seeking to restart nuclear power plants that meet strict new safety standards and is emphasizing nuclear energy’s importance as a base-load electricity source. In August 2015, Japan successfully restarted one nuclear reactor at the Sendai Nuclear Power Plant in Kagoshima prefecture, and several other reactors around the country have since resumed operations; however, opposition from local governments has delayed several more restarts that remain pending. Reforms of the electricity and gas sectors, including full liberalization of Japan’s energy market in April 2016 and gas market in April 2017, constitute an important part of Prime Minister Abe’s economic program.

In October 2015, Japan and 11 trading partners reached agreement on the Trans-Pacific Partnership (TPP), a pact that had promised to open Japan's economy to increased foreign competition and create new export opportunities for Japanese businesses. Japan was the first country to ratify the TPP in December 2016; the United States signaled its withdrawal from the TPP in January 2017, and in November 2017 the remaining 11 countries agreed on the core elements of a modified agreement, which they renamed the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP).

 

Source : CIA

 


Company summary

 

CARL ZEISS MEDITEC CO LTD

 

REGD NAME:   Carl Zeiss Meditec KK

MAIN OFFICE:  13-11 Yotsuya Honshiocho Shinjukuku Tokyo 160-0003 JAPAN

                                    Tel: 03-3355-0331      Fax: 03-3359-6284

 

URL:                 http://www.zeiss.co.jp

E-Mail address: (Thru the URL)

 

ACTIVITIES:     Import, wholesale of medical equipment, ophthalmic systems, other

BRANCHES:     Sendai, Nagoya, Osaka

OVERSEAS:     Germany (the parent)

 

OFFICERS:       SAKURE STEPHAN, PRES (Only phonetically spelled)

                       

Yen Amount:     In million Yen, unless otherwise stated

 

SUMMARY:      FINANCES        FAIR                 A/SALES          Yen 12,971 M

                                    PAYMENTS      REGULAR         CAPITAL           Yen 50 M

                                    TREND             STEADY           WORTH            Yen 13,050 M   

                                    STARTED         1991                 EMPLOYES      131

 

 

COMMENT

 

TRADING FIRM SPECIALIZING IN MEDICAL EQUIPMENT, OWNED BY CARL     ZEISS .MEDITEC AG, GERMANY

 

FINANCIAL SITUATION CONSIDERED FAIR AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS.

                       

MAX CREDIT LIMIT: ESTIMATED AT YEN 233.7 MILLION, ON 30 DAYS NORMAL TERMS.

 

 

HIGHLIGHTS

           

The subject company is a trading firm for import, export & wholesale of medical equipment, ophthalmic systems, other, owned by Carl Zeiss Meditec AG of Germany.  Products are imported by the Group firms.  Clients include national/public hospitals, university hospitals, other.

 

 


FINANCIAL INFORMATION

           

Financials are disclosed only partially.

 

The sales volume for Sept/2017 fiscal term amounted to Yen 12,971 million, a 1% up from Yen 12,786 million in the previous term.  The net profit was posted at Yen 592 million, compared with Yen 481 million a year ago.

 

For the current term ending Sept 2018 the net profit is projected at Yen 610 million, on a 3% rise in turnover, to Yen 13,360 million.

 

The financial situation is considered FAIR and good for ORDINARY business engagements.  Max credit limit is estimated at Yen 233.7 million, on 30 days normal terms.

 

 

REGISTRATION

    

            Date Registered:   Dec 1991

            Regd No.:         0111-01-017533 (Tokyo-Shinjukuku)

            Legal Status:       Limited Company (Kabushiki Kaisha)

            Authorized:         4,000 shares

            Issued:                1,000 shares

            Sum:                   Yen 50 million

  Major shareholders (%): Carl Zeiss Meditec AG (Germany) (51), Carl Zeiss Japan (49)

  No. of shareholders: 2

 

            Nothing detrimental is known as to the commercial morality of executives.

 

 

OPERATION

           

Activities: A trading firm for import, export & wholesale of medical equipment, ophthalmic systems, other –100%)

 

Clients: [Mfrs, wholesalers] National hospitals, university hospitals, ophthalmology clinics, medical trading firms, other  

No. of accounts: 350

Domestic areas of activities: Nationwide

Suppliers: [Mfrs, wholesalers] Carl Zeiss Meditec AG (Germany), Carl Zeiss Meditec Inc, other corporations, other

 

Payment record: Regular

 

Location: Business area in Tokyo.  Office premises at the caption address are owned and maintained satisfactorily.

 

Bank References:

                        Mizuho Bank (Yotsuya)

                        MUFG (Yotsuya)

                        Relations: Satisfactory

 

 

FINANCES

 

(In Million Yen)

Terms Ending:

 

30/09/2018

30/09/2017

30/09/2016

30/09/2015

Annual Sales

 

13,360

12,971

12,786

13,180

Recur. Profit

 

..

..

..

..

Net Profit

 

610

592

481

914

Total Assets

 

 

N/A

N/A

N/A

Net Worth

 

 

13,050

12,458

11,977

Capital, Paid-Up

 

 

50

50

50

Div.P.Share(¥)

 

 

0.00

0.00

0.00

<Analytical Data>

 

(%)

(%)

(%)

(%)

    S.Growth Rate

 

3.00

1.45

-2.99

-6.58

    Current Ratio

 

 

..

..

..

    N.Worth Ratio

 

 

..

..

..

    N.Profit/Sales

 

4.57

4.56

3.76

6.93

 

Notes: Financials are only partially disclosed.

Forecast (or estimated) figures for the 30/09/2018 fiscal term.

 

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

INR 64.92

UK Pound

1

INR 90.23

Euro

1

INR 80.54

Yen

1

INR 0.61

 

Note : Above are approximate rates obtained from sources believed to be correct

 

 

INFORMATION DETAILS

 

Analysis Done by :

DIV

 

 

Report Prepared by :

SYL

                                                


 

RATING EXPLANATIONS

 

Credit Rating

Explanation

Rating Comments

A++

Minimum Risk

Business dealings permissible with minimum risk of default

A+

Low Risk

Business dealings permissible with low risk of default

A

Acceptable Risk

Business dealings permissible with moderate risk of default

B

Medium Risk

Business dealings permissible on a regular monitoring basis

C

Medium High Risk

Business dealings permissible preferably on secured basis

D

High Risk

Business dealing not recommended or on secured terms only

NB

New Business

No recommendation can be done due to business in infancy stage

NT

No Trace

No recommendation can be done as the business is not traceable

 

NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors are as follows:

 

·         Financial condition covering various ratios

·         Company background and operations size

·         Promoters / Management background

·         Payment record

·         Litigation against the subject

·         Industry scenario / competitor analysis

·         Supplier / Customer / Banker review (wherever available)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.